Ali Rismani

469 total citations
25 papers, 222 citations indexed

About

Ali Rismani is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Ali Rismani has authored 25 papers receiving a total of 222 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 14 papers in Genetics and 9 papers in Oncology. Recurrent topics in Ali Rismani's work include Multiple Myeloma Research and Treatments (12 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Lymphoma Diagnosis and Treatment (6 papers). Ali Rismani is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Lymphoma Diagnosis and Treatment (6 papers). Ali Rismani collaborates with scholars based in United Kingdom, Netherlands and Canada. Ali Rismani's co-authors include Shirley D’Sa, Rakesh Popat, Kwee Yong, Neil Rabin, Νικόλαος Δικαίος, Margaret Hall‐Craggs, Magdalena Sokolska, Arash Latifoltojar, Charalampia Kyriakou and Steve Halligan and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and British Journal of Cancer.

In The Last Decade

Ali Rismani

23 papers receiving 220 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ali Rismani United Kingdom 7 134 93 56 55 41 25 222
Angela Rago Italy 10 179 1.3× 67 0.7× 136 2.4× 72 1.3× 15 0.4× 29 334
Ömür Gökmen Sevindik Türkiye 8 85 0.6× 104 1.1× 36 0.6× 33 0.6× 10 0.2× 52 205
Yasufumi Matsuda Japan 10 65 0.5× 70 0.8× 26 0.5× 93 1.7× 4 0.1× 27 259
Estelle Guérin France 9 117 0.9× 21 0.2× 72 1.3× 48 0.9× 9 0.2× 21 278
Lucía López‐Anglada Spain 9 158 1.2× 64 0.7× 75 1.3× 49 0.9× 20 0.5× 14 245
Güner Hayri Özsan Türkiye 9 92 0.7× 84 0.9× 35 0.6× 26 0.5× 9 0.2× 34 229
Joanna Rhodes United States 10 236 1.8× 62 0.7× 243 4.3× 33 0.6× 5 0.1× 45 361
Andrew Melville United Kingdom 8 43 0.3× 36 0.4× 26 0.5× 36 0.7× 14 0.3× 26 198
Bita Fakhri United States 11 118 0.9× 128 1.4× 57 1.0× 69 1.3× 13 0.3× 37 269
Tso-Fu Wang Taiwan 9 196 1.5× 85 0.9× 90 1.6× 22 0.4× 3 0.1× 16 299

Countries citing papers authored by Ali Rismani

Since Specialization
Citations

This map shows the geographic impact of Ali Rismani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ali Rismani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ali Rismani more than expected).

Fields of papers citing papers by Ali Rismani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ali Rismani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ali Rismani. The network helps show where Ali Rismani may publish in the future.

Co-authorship network of co-authors of Ali Rismani

This figure shows the co-authorship network connecting the top 25 collaborators of Ali Rismani. A scholar is included among the top collaborators of Ali Rismani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ali Rismani. Ali Rismani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kothari, Jaimal, Toby A. Eyre, Ali Rismani, et al.. (2024). PembroWM : A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia. British Journal of Haematology. 205(6). 2273–2281. 3 indexed citations
2.
Khwaja, Jahanzaib, Josephine M. I. Vos, Arjan J. Kwakernaak, et al.. (2023). Clinical and clonal characteristics of monoclonal immunoglobulin M‐associated type I cryoglobulinaemia. British Journal of Haematology. 204(1). 177–185. 9 indexed citations
3.
Khwaja, Jahanzaib, Ali Rismani, Aisling Carr, et al.. (2023). IBCL-099 Intensive Chemotherapy and Autologous Stem Cell (ASCT) Consolidation for Bing Neel Syndrome. Clinical Lymphoma Myeloma & Leukemia. 23. S448–S448. 1 indexed citations
4.
Khwaja, Jahanzaib, Helen O. McCarthy, Jaimal Kothari, et al.. (2022). Patient reported outcome measures in Waldenström macroglobulinaemia: A real‐world data analysis from the WMUK Rory Morrison Registry. SHILAP Revista de lepidopterología. 4(1). 221–225. 5 indexed citations
5.
Khwaja, Jahanzaib, Robert J. Baker, Ali Rismani, et al.. (2022). Bortezomib‐based therapy is effective and well tolerated in frontline and multiply pre‐treated Waldenström macroglobulinaemia including BTKi failures: A real‐world analysis. SHILAP Revista de lepidopterología. 3(4). 1330–1334. 8 indexed citations
6.
Kothari, Jaimal, Toby A. Eyre, Ali Rismani, et al.. (2022). Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia. Blood. 140(Supplement 1). 3624–3626. 2 indexed citations
7.
Rismani, Ali, et al.. (2021). Real World Experience on the Use of Ibrutinib Monotherapy in Waldenström Macroglobulinemia. Blood. 138(Supplement 1). 4507–4507. 2 indexed citations
8.
Khwaja, Jahanzaib, et al.. (2021). IgM Paraprotein-Associated Type 1 Cryoglobulinaemia: Clinical Characteristics and Outcomes. Blood. 138(Supplement 1). 4503–4503. 1 indexed citations
9.
Kyriakou, Charalampia, et al.. (2021). Autologous Haematopoietic Stem Cell Transplantation in Waldenström Macroglobulinemia: A Single-Centre 18-Year Experience. Blood. 138(Supplement 1). 3548–3548. 1 indexed citations
10.
Koutoukidis, Dimitrios A., Allan Hackshaw, Małgorzata Heinrich, et al.. (2020). Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design. British Journal of Cancer. 123(2). 187–195. 42 indexed citations
11.
Lindsay, Jindriska, Stephen Keddie, Aisling Carr, et al.. (2020). Neuropathy with IgM Gammopathy: Incidence, Characteristics and Management, a Rory Morrison W.M.U.K Registry Analysis. Blood. 136(Supplement 1). 1–2. 3 indexed citations
12.
Lunn, Michael P., Chandrashekar Hoskote, Aisling Carr, et al.. (2020). High-Dose Methotrexate Based Therapy for the Treatment of Bing Neel Syndrome. Blood. 136(Supplement 1). 12–13. 1 indexed citations
13.
Koutoukidis, Dimitrios A., Orla McCourt, Allan Hackshaw, et al.. (2018). Fatigue, Quality of Life, and Physical Fitness Following an Exercise Intervention in Survivors of Multiple Myeloma: A Randomised Controlled Trial Using a Zelen Design. Blood. 132(Supplement 1). 974–974. 1 indexed citations
14.
Chavda, Selina J, Paul Maciocia, Nicholas Counsell, et al.. (2018). A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1. British Journal of Haematology. 185(2). 350–353. 2 indexed citations
15.
Latifoltojar, Arash, Margaret Hall‐Craggs, Alan Bainbridge, et al.. (2017). Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction. European Radiology. 27(12). 5325–5336. 59 indexed citations
16.
Latifoltojar, Arash, Margaret Hall‐Craggs, Neil Rabin, et al.. (2016). Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response. British Journal of Haematology. 176(2). 222–233. 46 indexed citations
17.
Bradley, J.D., Shirley D’Sa, Charalampia Kyriakou, et al.. (2016). Vial Sharing of Bortezomib Is Logistically Feasible and Significantly Reduces Drug Wastage and the Cost of Myeloma Treatment. Blood. 128(22). 5956–5956. 7 indexed citations
18.
Melville, Andrew, Paul Maciocia, Faye Sharpley, et al.. (2016). Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience. Blood. 128(22). 3312–3312. 1 indexed citations
19.
Heinrich, Małgorzata, Orla McCourt, Bruce Paton, et al.. (2016). Physical and Psychological Factors Influencing Fatigue and Quality of Life in Multiple Myeloma Survivors: Preliminary Results from the Mascot Lifestyle Study. Blood. 128(22). 4776–4776. 2 indexed citations
20.
Sharpley, Faye, Stephen Schey, Ali Rismani, et al.. (2015). Outcome of Pomalidomide Therapy in Relapsed /Refractory Myeloma: A Uk Multi-Centre Experience. Clinical Lymphoma Myeloma & Leukemia. 15. e288–e289. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Angela Rago Breakdown of academic impact, for papers by Ömür Gökmen Sevindik Breakdown of academic impact, for papers by Yasufumi Matsuda Breakdown of academic impact, for papers by Estelle Guérin Breakdown of academic impact, for papers by Lucía López‐Anglada Breakdown of academic impact, for papers by Güner Hayri Özsan Breakdown of academic impact, for papers by Joanna Rhodes Breakdown of academic impact, for papers by Andrew Melville Breakdown of academic impact, for papers by Bita Fakhri Breakdown of academic impact, for papers by Tso-Fu Wang
Rankless by CCL
2026